Anthim: Completed Phase I enrollment

Elusys completed enrollment of 20 adult volunteers in a double-blind, placebo-controlled, U.S. Phase I trial evaluating 4, 8 or 16 mg/kg intramuscular injections of ETI-204. The compound has Orphan Dr...